Tongxing Environmental Protection Technology (003027.SZ) plans to acquire 100% equity of its subsidiary, Ma'anshan Haosheng.
Tongxing Technology (003027.SZ) announced that the company and its controlling subsidiary Tongxing Haosheng (Yibin) New Energy Technology Co., Ltd. ("Tongxing Haosheng") have signed a equity transfer agreement to acquire 100% equity of Ma'anshan Haosheng New Energy Technology Co., Ltd. ("Ma'anshan Haosheng") at an assessed value of 19.4931 million yuan.
Tongxing Environmental Protection Technology (003027.SZ) announced that the company and its holding subsidiary, Tongxing Haosheng (Yibin) New Energy Technology Co., Ltd. ("Tongxing Haosheng"), have signed a share transfer agreement to acquire 100% equity of Ma'anshan Haosheng New Energy Technology Co., Ltd. ("Ma'anshan Haosheng") at an evaluated value of 19.4931 million yuan.
The announcement stated that this equity acquisition is an important strategic layout in the company's development plan, which will help in the overall planning and development of the 180-acre land in Hanshan, Anhui, and solidify the foundation of the industrial layout.
Related Articles
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
